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ABSTRACT 
 
Objective: Multidrug resistance (MDR) transporters may be used as biomarkers to monitor 
disease progression in RA and as a predictive tool to establish responsiveness to biological 
therapy. In this multicenter clinical trial, we aimed to assess the predictive value of MDR1, 
MRP1 and BCRP activity measurement for biological therapeutic response in RA before as 
well as 4 to 6 and 12 weeks after the initiation of biological therapy. 
Methods: Peripheral blood samples were collected from 27 bDMARD Responders and 12 
Non-responders at the indicated time points as well as from 35 healthy controls. MDR 
activity (MAF) of MDR1, MRP1 and BCRP was measured in CD3+ and CD19+ cells using the 
Solvo MDQ Kit™ and cell surface staining by flow cytometry following PBMC isolation. 
Results: At the start of therapy, MAFC (composite MAF of MRP1 and MDR1) and MAFMDR 
values and at 4 to 6 weeks of treatment, MAFC, MAFMRP and MAFMDR values of CD3 cells 
were higher in Non-responders compared to Responders. ROC analysis revealed that RA 
patients with MAFC values above 21.3 in CD3 cells at the start of bDMARD therapy are likely 
to be Non-responders. At 4 to 6 weeks of treatment, MAFC values above 20.3, MAFMRP 
values above 6.0 and MAFMDR values above 13.9 in CD3 cells also predict unfavorable 
response. 
Conclusions: Our results indicate that the determination of MAFC values in CD3 cells of RA 
patients may be of predictive value prior to the initiation of biological therapy to establish 
whether the patient will demonstrate sufficient therapeutic response. 
 
KEYWORDS 
BCRP, bDMARD, MDR1, MRP1, multidrug resistance, T cells, therapeutic response 
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INTRODUCTION 
Rheumatoid arthritis (RA) affects approximately 0.5-1% of the population and causes chronic 
synovial inflammation eventually leading to joint destruction and disability [1]. Early 
diagnosis and immediate, effective therapy are crucial in order to prevent joint 
deterioration, functional disability and unfavorable disease outcome. The optimal 
management of RA is needed within 3-6 months after the onset of disease, therefore a very 
narrow „window of opportunity” is present to achieve remission or at least low disease 
activity (LDA) [2,3]. Therefore, it is very important to predict the efficacy of expensive 
biologicals at early stages of treatment. Although a new generation of drugs is available, 
there are no validated circulating biomarkers of prognostic use or to predict response to 
specific therapies [4]. 
Multidrug resistance (MDR-ABC) transporters (MDR1/P-gp/ABCB1; MRP1/ABCC1; 
BCRP/ABCG2) are important components in the development of drug resistance in 
malignancies [5] and in autoimmune conditions, such as RA [6]. Although studies of the 
crystal structure and function of MDR-ABC transporters suggest that they are not directly 
involved in the release of cytokines and chemokines, they may extrude other intracellular 
small molecules influencing the inflammatory balance. Thus they may play an important role 
in the pathogenesis of RA via influencing cell migration, proliferation and inflammation in an 
indirect manner. Therefore, MDR-ABC transporters may also be important biomarkers of 
disease progression in RA. The assessment of MDR protein activity may help physicians to 
evaluate how patients will respond to biological treatment and may support the decision 
whether there is a necessity to modify the treatment. 
The most important csDMARDs (including methotrexate, sulfasalazine, leflunomide and 
hydroxychloroquine) are substrates of MDR proteins. For this reason, MDR activity of RA 
patients on csDMARD therapy has been extensively studied and the expression, 
polymorphisms and activity of MDR proteins has been linked to therapeutic success of 
csDMARDs, especially that of methotrexate. However, little is known about the relation of 
MDR proteins to therapeutic success of biologicals, such as anti-TNF agents. Although these 
molecules do not enter the cell, and are therefore not substrates of MDR proteins, the 
endobiotics, such as the cytokines they target are known to interact with these transporters 
[7-9]. Through influencing the distribution of cytokines and other soluble factors within the 
cell and in its most proximal environment, the function of T- and B-cells may be affected by 
the activity of the transporters, balancing the effect of such factors on lymphocyte 
activation, proliferation, production of other cytokines and antibodies, etc. Therefore, MDR 
activity may be used as a biomarker of therapeutic success in RA and other autoimmune 
disorders. 
In this multicenter clinical trial, we aimed to assess the predictive value of flow-cytometry 
based multidrug resistance activity measurement for biological therapeutic response in 
rheumatoid arthritis. We aimed to assess the activity of three clinically relevant MDR 
proteins (MDR1, MRP1, BCRP) in CD3+ and CD19+ lymphocytes of RA patients before as well 
as 4 to 6 and 12 weeks after the initiation of biological therapy. 
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METHODS 
Patient Recruitment 
39 RA patients were recruited at the outpatient clinics of the Department of Rheumatology, 
University of Debrecen, Hungary and the Department of Rheumatology and Clinical 
Immunology, Charité, Berlin, Germany. Patients were sampled before the start of biological 
treatment as well as between 4 and 6 weeks and at 12 weeks of treatment. DAS28 and CRP 
values were also recorded at this time. Patients were regarded as non-responders (n = 12) if 
DAS28 values showed a decrease of less than 25% between the start of biologicals and at 12 
weeks of treatment (arbitrary cut-off). Patient characteristics as well as details of the 
therapy received are included in Table 1. 
Healthy controls (n = 35) were sampled at the Department of Rheumatology, University of 
Debrecen, Hungary on a single occasion. They had a negative history of autoimmune 
disorders including RA and a negative status upon physical examination as well as no 
infectious symptoms within three weeks before sampling. 
Exclusion criteria for all participants included chronic infectious diseases requiring systemic 
treatment, autoimmune diseases other than RA, immunodeficiencies, allergic diseases and 
hematological malignancies or solid tumors. 
Written informed consent was obtained from all participants and the study adhered to the 
tenets of the most recent revision of the Declaration of Helsinki. Ethical approval for the 
study was granted by local ethics committees of the University of Debrecen (TUKEB 
21018/2014/EKU) and Charité (EA1/193/10), respectively. 
Peripheral Blood Mononuclear Cell (PBMC) isolation 
6 mls of EDTA anticoagulated peripheral blood sample was collected. PBMCs were separated 
by density gradient centrifugation using Ficoll Histopaque-1077 (Cat. No: H8889, Sigma-
Aldrich, St. Louis, MO, USA) according to the manufacturer’s instructions. 
Flow Cytometry 
Measurements were conducted on a BD FACSCalibur flow cytometer (BD Biosciences, San 
Diego, CA, USA) equipped with 488 nm and 635 nm lasers or on a Miltenyi MACSQuant flow 
cytometer, equipped with 405nm, 488 nm and 638 nm lasers, respectively. 
The Solvo MDQ Kit™ was used strictly following the manufacturer’s instructions. In this 
assay, fluorescent reporter substrates are trapped in the cytoplasm and pumped out by MDR 
proteins depending on the presence or absence of highly selective inhibitors, allowing for 
quantitative, standardized assessment. PBMCs were loaded with fluorescent MDR activity 
reporter substrates (1.25 uM working solution of Calcein-AM for MDR1 and MRP1, em: 515 
nm, incubated for exactly 10 minutes followed by rapid centrifugation and 1 mM working 
solution of mitoxantrone for BCRP, em: 684 nm, respectively, incubated for exactly 30 
minutes followed by rapid centrifugation) and treated with highly selective MDR protein 
inhibitors (12.7 mM working solution of verapamil for MDR1 and MRP1, 2 mM working 
solution of indomethacin for MRP1 and 0.1 mM working solution of KO134 for BCRP, 
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respectively) to obtain multidrug activity factor (MAF) values (Figure 1). Note that the above 
working concentrations are further diluted upon addition to the cell suspension to avoid cell 
toxicity as described in the manufacturer’s instructions. 
Cell surface staining was applied to select CD3+ and CD19+ cells using anti-human CD3-PerCP 
and CD19-PE monoclonal antibodies (Cat. No: 345766 and 345789, respectively, both BD 
Biosciences) in case of Calcein-AM stained cells and anti-human CD3-FITC and CD19-PE 
monoclonal antibodies (Cat. No: 345764 and 345789, respectively, both BD Biosciences) in 
case of mitoxantrone stained cells according to the manufacturer’s instructions. Samples 
were run on a flow cytometer immediately following cell surface staining. 
Activities of multidrug transporters are reflected by the difference between the amount of 
Calcein/mitoxantrone accumulated in the presence or absence of the selective inhibitor(s). 
When calculating the MAF values, this accumulation difference is normalized to the dye 
uptake measured in the presence of the inhibitor. Thus, the result of the test becomes 
independent from factors influencing the cellular accumulation of Calcein/mitoxantrone 
other than the activity of the multidrug transporters. The inter-assay variability of the test is CV 
<10%. 
MAF values were calculated from the difference between the geometric mean fluorescent 
intensity (MFI) of cells with and without the highly selective inhibitors, respectively. 
MAFC (composite MAF of MRP1 and MDR1) = 100 x (Fmax – Fo) / Fmax 
MAF of MRP1 = 100 x (FMRP1 – Fo) / Fmax 
MAF of MDR1 = MAFC – MAF of MRP1 
MAF of BCRP = 100 x (FMX – F0) / FMX 
Fmax/FMX: Calcein/mitoxantrone fluorescence with verapamil or KO134, respectively 
Fo: fluorescence without inhibitor 
FMRP1: Calcein fluorescence with indomethacin 
Statistics 
Comparisons were made using the Kruskall-Wallis test or the Mann-Whitney test as the 
distribution of data appeared to be non-normal according to the Shapiro-Wilk test. p values 
< 0.05 were considered significant. Statistics were calculated using the GraphPad Prism 5 
software (La Jolla, CA, USA). 
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RESULTS 
DAS28 values decreased upon treatment in Responders in contrast to Non-responders. Of 
note, initial DAS28 values were higher in the Responder group compared to Non-responders 
(Table 2, Figure 2). Neither differences were observed in CRP values between the two group, 
nor changes in CRP were demonstrated upon treatment. 
MAF of MRP1 in CD3 cells was higher at 12wk in Non-responders compared to Controls. No 
other statistically significant difference was noted in MAF values between Controls and RA 
patients. 
Control values were within the reference range established in our earlier study [10]. 
At the start of therapy, MAFC and MAFMDR values of CD3 cells were higher in Non-
responders compared to Responders. At 6wk, MAFC, MAFMRP and MAFMDR values of CD3 
cells as well as MAFMRP values of CD19 cells were higher in Non-responders compared to 
Responders (Table 2). 
No significant changes were demonstrated in MAF values in the respective RA patient groups 
with the progress of treatment (Figure 3). 
No difference was demonstrated in MAFBCRP values in CD3 or CD19 cells between 
Responders and Non-responders. 
ROC analysis was performed to evaluate the predictive value of MAF for response to 
treatment in RA patients at the start of biological therapy and at 6wk. Cut-off thresholds 
were calculated for MAF values with ROCs of adequate p and AUC values (Figure 4). Patients 
with MAF values above the respective cut-off thresholds are likely to be Non-responders to 
treatment (MAFC of CD3 cells at 0wk: p = 0.043, AUC = 0.68; MAFC of CD3 cells at 6wk: p = 
0.033, AUC = 0.72; MAFMDR on CD3 cells at 6wk: p = 0.048, AUC = 0.70; MAFMRP on CD3 
cells at 6wk: p = 0.049, AUC = 0.69). 
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DISCUSSION 
Our results indicate that at the start of therapy, MAFC and MAFMDR values, and later at 4 to 
6 weeks of treatment, MAFC, MAFMRP and MAFMDR values of CD3 cells were higher in 
Non-responders to bDMARD compared to Responders among RA patients. ROC analysis 
revealed that RA patients with MAFC values above 21.3 in CD3 cells at the start of bDMARD 
therapy are likely to be Non-responders. 
While MDR1 expression on healthy CD4+ and CD19+ lymphocytes is only marginal, 
significant upregulation was demonstrated in RA patients [11,12] as a result of the presence 
of danger-associated molecular patterns (DAMPs). Furthermore, the expression level of 
MDR1 was significantly elevated in methotrexate (MTX) non-responder patients compared 
to responders. The YB-1 transcriptional factor may have an essential role in the regulation of 
MDR1 in lymphocytes of RA patients by translocation from the cytoplasm into the nucleus. 
Inflammation-derived TNF-a appears to play a crucial role in this phenomenon [13]. 
In an earlier study, Rhodamine 123 was used as a substrate of MDR1 and verapamil as 
transporter inhibitor [14]. Flow cytometry based analysis did not find any correlations 
between MTX responders and non-responders at baseline, however in non-responders the 
functional activity was upregulated 4 months following therapy.  
In a more recent study, the activity of MDR1 and MRP1 was investigated on different 
leukocyte subsets, namely granulocytes, monocytes, lymphocytes, CD4+, CD8+ and CD19+ 
cells from RA patients and controls (traumatic injury patients and healthy volunteers, 
respectively). Based on DAS28 scores, RA patients fell into MTX responder and non-
responder groups. Since side effects easily develop during MTX treatment, an additional 
MTX intolerant group was generated with intolerable side effects. In case of granulocytes, 
the functional activity of MRP1 was significantly higher in MTX responders vs. MTX non-
responders. Furthermore, even higher functional activity was demonstrated in MTX 
intolerant individuals in comparison with MTX responders. Therefore, the authors concluded 
that determining MAF values might be useful in predicting MTX intolerance in order to avoid 
harmful side effects of MTX therapy [15]. 
Although the role of MDR transporter activity in the prediction of response to MTX has been 
characterized in RA, little is known about the relation of MDR proteins to therapeutic success 
of biologicals. In contrast to MTX and other csDMARDs, these molecules do not enter the 
cell, and are therefore not substrates of MDR proteins. However, the cytokines they target 
may indirectly interact with these transporters [7-9]. For instance, a recent study described 
that stimulation with TNF-a induced MDR1 and MRP1 expression via NF-kB signaling in 
astrocytes [16]. Therefore, we hypothesized that MDR activity may be used as a biomarker 
to predict therapeutic success in RA. A similar crosstalk in lymphocytes could provide the 
molecular basis of the findings of our clinical study, yet to be confirmed in future 
investigations. 
Our ROC analysis revealed that the assessment of multidrug activity of peripheral blood 
lymphocytes carries predictive value for response to bDMARD treatment in RA patients at 
the start of therapy. Patients with MAF values above the cut-off thresholds are likely to be 
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Non-responders to treatment. Of note, these cut-off values are all below the respective 
reference ranges in healthy individuals established in our earlier study. 
Although baseline MAF values before the start of bDMARD therapy did not differ between 
healthy controls and the RA patient groups, such differences were already present between 
Responder and Non-responder RA patients in case of T cells. Future studies may be able to 
explore whether differences in MAF values are present in therapy naïve RA patients 
compared to healthy controls as well as the changes in the activity of the studied 
transporters over the course of csDMARD treatment until reaching the need for bDMARD 
therapy. This information could provide more insight into the pathophysiological role of 
these transporters and may enable even earlier prediction of RA treatment response. 
Interestingly, no significant changes of MAF values within the respective RA patient groups 
were demonstrated with the progress of treatment (Figure 3). However, considerable intra- 
and inter-patient variations were observed within both patient groups in these values. This 
observation may be related to limitations of our study, namely the relatively small number 
of patients included in each group and in particular the heterogeneity of the bDMARD 
treatment received. A larger number of patients in future studies will allow to create and compare 
homogenous patient groups in terms of the therapy applied. 
 
In conclusion, our results indicate that the determination of MAFC values in CD3 cells of RA 
patients may be of predictive value prior to the initiation of biological therapy to establish 
whether the patient will demonstrate sufficient therapeutic response. Measuring MAFC, 
MAFMRP and MAFMDR values in CD3 cells at 4 to 6 weeks after the start of treatment 
further improves the accuracy of prediction as to whether adequate therapeutic response 
may be expected. 
 
 
LIST OF ABBREVIATIONS 
ABC  ATP-binding cassette 
bDMARD biological disease modifying antirheumatic drug 
BCRP  breast cancer resistance protein 
CRP  C-reactive protein 
DAS  disease activity score 
csDMARD conventional synthetic disease modifying antirheumatic drug 
MAF  MDR activity factor 
MDR  multidrug resistance 
MRP  multidrug resistance protein 
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MTX  methotrexate 
PBMC  peripheral blood mononuclear cell 
RA  rheumatoid arthritis  
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FIGURE LEGENDS 
 
Figure 1. The effects of highly selective inhibitors of MRP1 (indomethacin) and MRP1 + 
MDR1 (verapamil) on calcein substrate fluorescence intensity at high (A) and low (B) 
transporter activity, and the effects of the highly selective inhibitor of BCRP (KO134) on 
mitoxantrone substrate fluorescence intensity at high (C) and low (D) transporter activity in 
CD3 cells – representative samples of RA patients 
 
Figure 2. DAS28 values at different sampling time points in Responder and Non-responder 
RA patients. *p < 0.05 vs. 0wk 
 
Figure 3. Individual changes of MAF values on CD3 cells over time in Responder (n = 27) and Non-
responder (n=12) RA patients. No significant changes were demonstrated in MAF values in the 
respective RA patient groups with the progress of treatment.  
 
Figure 4. ROC analysis was performed to evaluate the predictive value of MAF for response 
to treatment in RA patients at the start of biological therapy and at 6wk. Patients with MAF 
values above the respective cut-off thresholds are likely to be Non-responders to treatment. 
MAFC of CD3 cells at 0wk: p = 0.043, AUC = 0.68; MAFC of CD3 cells at 6wk: p = 0.033, AUC = 
0.72; MAFMDR on CD3 cells at 6wk: p = 0.048, AUC = 0.70; MAFMRP on CD3 cells at 6wk: p = 
0.049, AUC = 0.69 
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Table 1. Clinical characteristics of Responder and Non-responder RA patients as well as healthy controls. Data are expressed as median (IQR) for continuous 
variables and as number (percentage) for categorical variables. MTX – methotrexate 
 
 Healthy controls (n = 35) Responder (n = 27) Non-responder (n = 12) 
Age (years) 54 (42-62) 56 (49-61) 51 (39-61) 
Gender (male/female) 4/31 2/25 1/11 
RA duration (years) - 10 (5-14) 8.5 (5-15) 
No. of patients receiving MTX - 15 (56%) 6 (50%) 
No. of patients receiving prednisolone - 9 (33%) 5 (42%) 
No. of patients receiving adalimumab - 2 (7%) 1 (8%) 
No. of patients receiving certolizumab pegol - 5 (19%) 3 (25%) 
No. of patients receiving etanercept - 7 (26%) 3 (25%) 
No. of patients receiving abatacept - 13 (48%) 5 (42%) 
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Table 2. Activity of various MDR transporters on CD3 and CD19 cells in RA patients and healthy controls. Data are expressed as median (IQR),
 
p < 0.05 
a
 vs 
Control, 
b
 vs Responder, 
c
 vs 0 wk value. MAFC – composite multidrug activity factor (of MRP1 and MDR1 activity), MAFMRP– multidrug activity factor of 
MRP1, MAFMDR – multidrug activity factor of MDR1, MAFBCRP – multidrug activity factor of BCRP 
  
  0 wk 6 wk 12 wk 
 Control Responder Non-responder Responder Non-responder Responder Non-responder 
DAS28 - 5.94 (5.11-6.17) 4.65
b
 (3.33-5.23) 3.71
c
 (2.79-4.45) 3.93 (3.14-4.50) 3.00
 c
 (2.23-3.67) 3.90
b
 (2.81-4.90) 
CRP - 11.1 (2.6-16.6) 8.4 (1.4-15.1) 4.4 (1.3-7.9) 4.4 (1.5-10.4) 3.7 (2.1-5.6) 7.5 (2.7-11.6) 
CD3 MAFC 18.3 (14.7-22.9) 18.9 (14.0-25.2) 23.5
b
 (17.1-33.7) 17.1 (12.3-22.6) 22.7
b
 (16.7-29.2) 18.3 (15.7-24.2) 25.2 (15.9-30.7) 
CD3 MAFMRP 3.1 (1.2-5.7) 4.8 (0.0-8.0) 5.7 (2.2-8.0) 2.2 (0.0-7.9) 8.4
b
 (2.1-11.3) 5.7 (3.7-8.5) 7.7
a
 (4.0-11.6) 
CD3 MAFMDR 14.6 (12.5-18.1) 12.9 (11.0-16.7) 19.1
b
 (11.2-24.0) 12.4 (11.2-15.4) 15.8
b
 (14.3-18.7) 12.5 (9.2-17.5) 13.6 (6.0-20.0) 
CD3 MAFBCRP 2.5 (0.8-5.7) 3.1 (0.0-4.4) 5.0 (2.0-8.0) 2.0 (0.0-5.5) 3.9 (2.5-10.7) 1.4 (0.0-4.3) 4.5 (1.8-5.8) 
CD19 MAFC 12.8 (8.9-17.9) 15.1 (8.1-22.1) 20.6 (13.5-31.0) 13.2 (9.3-20.4) 17.6 (11.4-27.2) 17.4 (13.1-22.3) 17.6 (9.2-25.9) 
CD19 MAFMRP 2.2 (0.0-6.3) 0.9 (0.0-7.7) 4.4 (0.0-5.8) 0.6 (0.0-5.1) 6.8
b
 (0.5-9.6) 3.2 (0.3-6.8) 5.1 (1.9-10.9) 
CD19 MAFMDR 9.9 (8.0-14.0) 11.1 (6.0-16.3) 15.7 (8.4-25.4) 11.4 (5.3-14.8) 13.6 (8.6-17.7) 14.0 (7.1-17.7) 8.8 (1.9-15.7) 
CD19 MAFBCRP 3.8 (1.0-6.3) 3.1 (0.7-7.0) 4.5 (0.0-11.0) 2.7 (0.0-5.2) 5.0 (3.1-8.4) 2.9 (1.3-5.1) 3.0 (1.8-3.7) 
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